Comparison of Adjunctive Quetiapine Versus Adjunctive Haloperidol in Combination with Sodium Valproate for Treatment of Patients with Mania or Mixed Feature Bipolar I Disorder: A Randomized Double-Blind Clinical Trial Study

被引:0
|
作者
Samiei, Mercedeh [1 ]
Sepehrifar, Zahra [1 ]
Daneshmand, Reza [2 ]
Sadighi, Gita [1 ]
机构
[1] Univ Social Welfare & Rehabil Sci, Dept Psychiat, Tehran, Iran
[2] Univ Social Welfare & Rehabil Sci, Subst Abuse & Dependence Res Ctr, Tehran, Iran
关键词
Bipolar Disorder; Haloperidol; Mania; Sodium Valproate; Quetiapine; Young Mania Rating; COST-EFFECTIVENESS; PLUS;
D O I
10.5812/ijpbs.90106
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Acute mania causes many problems for the patient and others. Therefore, it is very important to eliminate the symptoms quickly. Objectives: The present study made the individual comparison of the therapeutic effects of sodium valproate combined with quetiapine or haloperidol as an add-on among patients with bipolar I disorder experiencing an episode of mania or mixed feature admitted to a Psychiatric Center in Tehran. Methods: The present study was a double-blind clinical randomized trial conducted on 36 patients. All patients were investigated by the Young Mania Rating Scale (YMRS). The study lasted six weeks in total (after raising drug dosage to the maximum level). We prescribed sodium valproate 15 mg/kg plus quetiapine 500 mg daily in one group and sodium valproate 15 mg/kg plus haloperidol 10 mg daily in the other group. In addition, an equivalent dosage of quetiapine and haloperidol was prescribed. This study used different data analysis methods such as Paired t test, ANOVA, and chi-square test. Results: The YMRS scores did not show any statistically significant difference between quetiapine and haloperidol receiving groups (P > 0.05). Conclusions: This paper argued that a combination of sodium valproate with either quetiapine or haloperidol could be effective in the management of acute mania or mixed bipolar I disorder to reduce the severity and duration of symptoms, although there was no statistically significant difference between the efficacy of these two pharmacological therapies.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] A double-blind, randomized, placebo-controlled plus open trial of adjunctive suvorexant for treatment-resistant insomnia in patients with bipolar disorder
    Cafaro, Rita
    Macellaro, Monica
    Suppes, Trisha
    Dell'Osso, Bernardo
    Ketter, Terence
    Miller, Shefali
    Chang, Lauren
    Lyu, Jihun
    Wang, Po
    BIPOLAR DISORDERS, 2023, 25 : 82 - 82
  • [32] A double-blind, randomized, placebo-controlled plus open trial of adjunctive suvorexant for treatment-resistant insomnia in patients with bipolar disorder
    Cafaro, Rita
    Macellaro, Monica
    Suppes, Trisha
    Dell'Osso, Bernardo
    Ketter, Terence
    Ostacher, Michael
    Miller, Shefali
    Chang, Lauren
    Lyu, Jihun
    Wang, Po W.
    CNS SPECTRUMS, 2024, 29 (05) : 376 - 384
  • [33] Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran
    Faridhosseini, Farhad
    Talaei, Ali
    Shahini, Najmeh
    Salimi, Zanireh
    Eslamzadeh, Mahboubeh
    Ahrari, Samira
    Pourgholami, Meysam
    Khadem-Rezaiyan, Majid
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2023, 38 (05) : 336 - 341
  • [34] Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial
    Aida Khadivi
    Parnian Shobeiri
    Sara Momtazmaneh
    Farhaneh-Sadat Samsami
    Mohammadreza Shalbafan
    Elham Shirazi
    Shahin Akhondzadeh
    Psychopharmacology, 2022, 239 : 551 - 559
  • [35] Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: A randomized, double-blind study
    Khan, Arifulla
    Atkinson, Sarah
    Mezhebovsky, Irina
    She, Fahua
    Leathers, Todd
    Pathak, Sanjeev
    ANNALS OF CLINICAL PSYCHIATRY, 2014, 26 (01) : 3 - 18
  • [36] A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF ADJUNCTIVE ARMODAFINIL FOR THE TREATMENT OF MAJOR DEPRESSION ASSOCIATED WITH BIPOLAR I DISORDER
    Frye, M. A.
    Ketter, T. A.
    Yang, R.
    Calabrese, J. R.
    VALUE IN HEALTH, 2013, 16 (03) : A55 - A56
  • [37] Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial
    Khadivi, Aida
    Shobeiri, Parnian
    Momtazmaneh, Sara
    Samsami, Farhaneh-Sadat
    Shalbafan, Mohammadreza
    Shirazi, Elham
    Akhondzadeh, Shahin
    PSYCHOPHARMACOLOGY, 2022, 239 (02) : 551 - 559
  • [38] A double-blind, placebo-controlled, multicenter trial of adjunctive armodafinil for the treatment of major depression associated with bipolar I disorder
    Ketter, T. A.
    Calabrese, J. R.
    Yang, R.
    Frye, M. A.
    BIPOLAR DISORDERS, 2013, 15 : 88 - 88
  • [39] A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania
    Mousavi, Seyed Yaser
    Khezri, Rasoul
    Karkhaneh-Yousefi, Mohammad-Ali
    Mohammadinejad, Payam
    Gholamian, Faezeh
    Mohammadi, Mohammad Reza
    Zeinoddini, Atefeh
    Akhondzadeh, Shahin
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (06) : 494 - 500
  • [40] Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study
    Sachs, G
    Chengappa, KNR
    Suppes, T
    Mullen, JA
    Brecher, M
    Devine, NA
    Sweitzer, DE
    BIPOLAR DISORDERS, 2004, 6 (03) : 213 - 223